Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | Journal Article | ||||||||||||
| PMID | (41719512) | ||||||||||||
| Authors | Hamidi S, Subbiah V, Cabanillas ME, Sherman SI, Vodopivec DM, Dadu R, Hu MI | ||||||||||||
| Title | Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid Carcinoma. | ||||||||||||
|
|||||||||||||
| URL | |||||||||||||
| Abstract Text | |||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK RET C620R | medullary thyroid carcinoma | predicted - resistant | Pralsetinib | Case Reports/Case Series | Actionable | In a clinical case study, EML4-ALK (e5:e19) was identified at the time of progression on Gavreto (pralsetinib) treatment in a patient with medullary thyroid carcinoma harboring RET C620R (PMID: 41719512). | 41719512 |
| RET C620R | medullary thyroid carcinoma | predicted - sensitive | Pralsetinib | Case Reports/Case Series | Actionable | In a clinical case study, Gavreto (pralsetinib) treatment resulted in a partial response in a patient with medullary thyroid carcinoma harboring germline RET C620R (PMID: 41719512). | 41719512 |